Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck’s patent was invalid. He said it did not meet a requirement that it disc

The Week in Review: March 24, 2017 – March 31, 2017

Friday, March 31, 2017 News Recap Canada Good news from Saskatchewan this week: The Sask. Ministry of Health has signed a deal similar to those in BC, Ontario and Quebec and will soon be paying for six new drugs. The province estimates 12,000 people suffer from HepC in the province (Saskatchewan expands coverage for 6 hepatitis C drugs). Bad news from Calgary, Alberta: Alberta Health Services has shut down an illegal dental clinic in Calgary that...

Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni. The jury in Delaware reached the verdict following a nearly two-week trial, finding that a patent acquired by Merck in 2014 on hepatitis C treatments was valid. "The jury's verdict upholds patent protections that are essential to the development of new medica

Gilead Again Defends Against Lawsuits Over Patents for Hepatitis C Treatments

The University of Minnesota filed a lawsuit against Gilead Sciences, maintaining that the pharmaceutical company infringed on a patent when it marketed 3 medications for the treatment of the hepatitis C virus (HCV) containing the drug sofosbuvir, including the company’s brand-name drugs Sovaldi, Harvoni, and Epclusa, reported STAT. The university’s lawsuit states that all 3 drugs are covered by patent rights assigned to the university by Carston Wagner,...

UPDATE 1-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute

By Rory Carroll and Andrew ChungA federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs, Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014

Merck Wins Hepatitis C Drug Patent Claim Against Gilead

A federal jury on Tuesday upheld the validity of two Merck patents in a dispute with Gilead Sciences, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.The verdict in federal court in San Jose, Calif., is a setback for Gilead, whose drugs Sovaldi and Harvoni brought in $19.2 billion in worldwide sales last year. Merck has demanded more than $2 billion in damages and a royalty of 10